Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/RAD21_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RAD21_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RAD21_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RAD21_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RAD21_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RAD21_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/RAD21_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RAD21_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RAD21_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00900687 | Prostate | BPH | positive regulation of cell cycle process | 58/3107 | 236/18723 | 1.03e-03 | 6.46e-03 | 58 |
GO:19019913 | Prostate | BPH | negative regulation of mitotic cell cycle phase transition | 46/3107 | 179/18723 | 1.24e-03 | 7.51e-03 | 46 |
GO:01400144 | Prostate | BPH | mitotic nuclear division | 67/3107 | 287/18723 | 1.87e-03 | 1.07e-02 | 67 |
GO:200125215 | Prostate | Tumor | positive regulation of chromosome organization | 34/3246 | 82/18723 | 2.41e-07 | 5.65e-06 | 34 |
GO:003304414 | Prostate | Tumor | regulation of chromosome organization | 57/3246 | 187/18723 | 6.74e-06 | 1.02e-04 | 57 |
GO:000734613 | Prostate | Tumor | regulation of mitotic cell cycle | 113/3246 | 457/18723 | 3.37e-05 | 3.96e-04 | 113 |
GO:004477214 | Prostate | Tumor | mitotic cell cycle phase transition | 106/3246 | 424/18723 | 3.61e-05 | 4.21e-04 | 106 |
GO:004578714 | Prostate | Tumor | positive regulation of cell cycle | 81/3246 | 313/18723 | 8.45e-05 | 8.46e-04 | 81 |
GO:001063917 | Prostate | Tumor | negative regulation of organelle organization | 87/3246 | 348/18723 | 1.73e-04 | 1.53e-03 | 87 |
GO:004578611 | Prostate | Tumor | negative regulation of cell cycle | 93/3246 | 385/18723 | 3.79e-04 | 2.95e-03 | 93 |
GO:004593011 | Prostate | Tumor | negative regulation of mitotic cell cycle | 60/3246 | 235/18723 | 9.42e-04 | 6.18e-03 | 60 |
GO:190199011 | Prostate | Tumor | regulation of mitotic cell cycle phase transition | 73/3246 | 299/18723 | 1.12e-03 | 7.14e-03 | 73 |
GO:190199111 | Prostate | Tumor | negative regulation of mitotic cell cycle phase transition | 45/3246 | 179/18723 | 5.17e-03 | 2.49e-02 | 45 |
GO:009006813 | Prostate | Tumor | positive regulation of cell cycle process | 56/3246 | 236/18723 | 7.35e-03 | 3.28e-02 | 56 |
GO:014001412 | Prostate | Tumor | mitotic nuclear division | 66/3246 | 287/18723 | 8.19e-03 | 3.60e-02 | 66 |
GO:014001415 | Skin | cSCC | mitotic nuclear division | 149/4864 | 287/18723 | 3.59e-21 | 6.43e-19 | 149 |
GO:000081912 | Skin | cSCC | sister chromatid segregation | 110/4864 | 202/18723 | 5.56e-18 | 6.58e-16 | 110 |
GO:000007012 | Skin | cSCC | mitotic sister chromatid segregation | 96/4864 | 168/18723 | 9.55e-18 | 1.05e-15 | 96 |
GO:000705912 | Skin | cSCC | chromosome segregation | 161/4864 | 346/18723 | 8.34e-17 | 8.57e-15 | 161 |
GO:003304417 | Skin | cSCC | regulation of chromosome organization | 100/4864 | 187/18723 | 8.97e-16 | 7.70e-14 | 100 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RAD21 | SNV | Missense_Mutation | | c.1522G>C | p.Glu508Gln | p.E508Q | O60216 | protein_coding | tolerated(0.18) | probably_damaging(0.932) | TCGA-A2-A0EW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
RAD21 | SNV | Missense_Mutation | novel | c.1627N>T | p.Asp543Tyr | p.D543Y | O60216 | protein_coding | tolerated(0.06) | possibly_damaging(0.67) | TCGA-A7-A6VV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
RAD21 | SNV | Missense_Mutation | | c.121N>C | p.Val41Leu | p.V41L | O60216 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
RAD21 | SNV | Missense_Mutation | | c.268N>T | p.Arg90Trp | p.R90W | O60216 | protein_coding | deleterious(0) | benign(0.167) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAD21 | SNV | Missense_Mutation | | c.1485N>T | p.Glu495Asp | p.E495D | O60216 | protein_coding | tolerated(0.4) | benign(0.005) | TCGA-C8-A134-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
RAD21 | SNV | Missense_Mutation | | c.1130N>G | p.Ala377Gly | p.A377G | O60216 | protein_coding | tolerated(0.25) | probably_damaging(0.978) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
RAD21 | insertion | Nonsense_Mutation | novel | c.1641_1642insAGAAGAATAAATTCTAAGTCTTAAACAACAACCTCAAT | p.Asp548ArgfsTer8 | p.D548Rfs*8 | O60216 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAD21 | SNV | Missense_Mutation | novel | c.185N>A | p.Gly62Glu | p.G62E | O60216 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A3Y4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RAD21 | SNV | Missense_Mutation | | c.1450N>C | p.Asp484His | p.D484H | O60216 | protein_coding | deleterious(0.04) | benign(0.157) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RAD21 | SNV | Missense_Mutation | novel | c.426N>C | p.Glu142Asp | p.E142D | O60216 | protein_coding | tolerated(0.15) | probably_damaging(0.956) | TCGA-JW-AAVH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |